Moderna, Inc. (MRNA): Price and Financial Metrics

Moderna, Inc. (MRNA)

Today's Latest Price: $129.65 USD

0.07 (-0.05%)

Updated Jan 15 4:00pm

Add MRNA to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 483 in Biotech

See all "A" rated Strong Buy stocks

MRNA Stock Summary

  • MRNA's price/sales ratio is 208.07; that's higher than the P/S ratio of 97.86% of US stocks.
  • With a year-over-year growth in debt of 514.07%, Moderna Inc's debt growth rate surpasses 96.56% of about US stocks.
  • Revenue growth over the past 12 months for Moderna Inc comes in at 202.43%, a number that bests 96.95% of the US stocks we're tracking.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Moderna Inc are VRTX, BGNE, REGN, BNTX, and MRVL.
  • Visit MRNA's SEC page to see the company's official filings. To visit the company's web site, go to

MRNA Stock Price Chart Interactive Chart >

Price chart for MRNA

MRNA Price/Volume Stats

Current price $129.65 52-week high $178.50
Prev. close $129.72 52-week low $17.91
Day low $126.58 Volume 15,769,500
Day high $133.29 Avg. volume 16,786,420
50-day MA $119.03 Dividend yield N/A
200-day MA $77.74 Market Cap 51.30B

Moderna, Inc. (MRNA) Company Bio

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Derrick J. Rose, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA

MRNA Latest News Stream

Event/Time News Detail
Loading, please wait...

MRNA Latest Social Stream

Loading social stream, please wait...

View Full MRNA Social Stream

Latest MRNA News From Around the Web

Below are the latest news stories about Moderna Inc that investors may wish to consider to help them evaluate MRNA as an investment opportunity.

This Is the Best News Yet for Moderna's COVID Vaccine | The Motley Fool

The company avoided a much-dreaded scenario.

Flipboard | January 17, 2021

Swiss to get Moderna vaccine in tranches until mid-year - Blick

Moderna will deliver 7.5 million doses of COVID-19 vaccine to Switzerland in batches in the months ahead, putting the country among the world leaders in inoculating its population, the head of Moderna's European business said. Staner said Switzerland would not get privileged treatment because it was the first country to chose Moderna as a supplier. Swiss regulators have approved vaccines from Moderna and from Pfizer with partner BioNTech.

Yahoo | January 17, 2021

GPs and nurses get Moderna jab at vaccination centres

Around 1,800 frontline medical workers are receiving a Covid-19 vaccine as part of a targeted vaccination programme this weekend.

RTE | January 16, 2021

Gilead Stock 2021: Why The Biotech Stock Isn't Depending On Covid Drugs

Gilead Sciences isn't betting its 2021 on coronavirus treatment Veklury. But the biotech company still sees plenty of catalysts in oncology, virology and inflammation for Gilead stock.

Yahoo | January 15, 2021

Doctor: ‘People are craving really clear information about what is happening’ on the vaccine front

Suzanne Judd, Ph.D., Epidemiologist at the University of Alabama at Birmingham School of Public Health, joins Yahoo Finance's Sibile Marcellus to break down the latest coronavirus developments.

Yahoo | January 15, 2021

Read More 'MRNA' Stories Here

MRNA Price Returns

1-mo -7.54%
3-mo 89.63%
6-mo 72.11%
1-year N/A
3-year N/A
5-year N/A
YTD 24.10%
2020 434.10%
2019 28.09%
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7344 seconds.